The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Laura Banaszynski, Ph.D., University of Texas Southwestern Medical Center – Laura Banaszynski, PhD, has always been passionate about science. After training as a chemical biologist, her innate curiosity pushed her to explore the mysteries of cells as a basic researcher.
The experience of NETs profoundly changes people’s lives. Fatigue, isolation, worry, and bothersome physical side effects can disrupt daily activities. Here are some simple steps to maintain optimal health and balance during and after cancer care.
A NETRF-funded researcher earned the highest honor from the American Society of Clinical Oncology (ASCO) on June 3, 2017 as part of its Annual Meeting in Chicago. Carl June, MD, University of Pennsylvania, received the David A. Karnofsky Memorial Award for outstanding contributions to cancer research, diagnosis, and treatment.
Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.
Growing small intestinal organoids in a petri dish. Sequencing the “runaway” DNA of a pancreatic neuroendocrine tumor from a blood sample. Evaluating whether environmental or infectious agents contribute to the development of NETs. The research programs funded by NETRF this year push the search for the causes of this disease to the horizon of emerging scientific research.
(April 25, 2017, Boston, MA)—The Neuroendocrine Tumor Research Foundation (NETRF) today announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates
NETRF is pleased to announce awards for world-class research to explore the potential of immunotherapy in NETs. This rapidly expanding class of therapies has proven
Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical
The Neuroendocrine Tumor Research Foundation is excited to be working with Pattern.org to empower patients to direct their excess cancer tissue samples to research projects.
